Shandong Fenghuang Pharmaceutical

Shandong Fenghuang Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise based in Linyi, Shandong, China. Founded in 1992, the company integrates research, development, and large-scale manufacturing of both Traditional Chinese Medicine (TCM) and Western chemical pharmaceuticals. It is particularly prominent in the hepatology sector, where its core product, Wuzhiling Capsule, is widely utilized for treating liver inflammation and chronic hepatitis. The company maintains multiple GMP-certified production lines for diverse formulations, including tablets, capsules, and injections. Listed on the National Equities Exchange and Quotations (NEEQ) since 2015, Fenghuang Pharmaceutical continues to expand its portfolio in cardiovascular, gastrointestinal, and anti-infective therapeutic areas.